Skip to main navigation

Platforms
- Platforms
- GoCARTM™ Technology
Pipeline
Publications
- Scientific Publications
About Us
Investors & Media
Search Close

Mobile Menu Mobile Close

Platforms

Platforms
GoCARTM™ Technology

Pipeline

Pipeline
GoCAR-T®
RIVO-CEL™

Publications

Scientific Publications

About Us

Management Team
Board of Directors
Advisory Board
Careers

Investors & Media

Investor Center
News & Events
Stock Information
Financial Information
- Annual Reports & Proxies
- SEC Filings
Corporate Governance
Investor FAQ
Contact Us

Search

Inpage Nav - News & Events

Press Releases
Events and Presentations
Email Alerts

Press Releases

Press Releases

Year

Date

Title
12/10/20

Bellicum Enrolls First Patient in Phase 1/2 Clinical Trial for BPX-603
12/07/20

Bellicum Reports Clinical Hold Placed on BPX-601 Phase 1/2 Clinical Trial
11/05/20

Bellicum Reports Third Quarter 2020 Financial Results and Provides Operational Update
11/03/20

Bellicum Pharmaceuticals Announces Closing of $25.0 Million Underwritten Offering
10/29/20

Bellicum Announces $25.0 Million Underwritten Offering Priced At-The-Market
10/29/20

Bellicum Announces Interim BPX-601 Data and Corporate Restructuring
09/30/20

Bellicum Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
09/28/20

Bellicum to Participate in Two Upcoming Virtual Conferences
09/02/20

Bellicum to Participate in Two Upcoming Virtual Investor Conferences
08/31/20

Bellicum Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
08/06/20

Bellicum Reports Second Quarter 2020 Financial Results and Provides Operational Update
07/31/20

Bellicum Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
07/30/20

Bellicum to Report Second Quarter 2020 Financial Results and Provide Corporate Update
06/15/20

Bellicum Receives FDA IND Clearance to Initiate a Phase 1/2 Clinical Trial for BPX-603, a Dual-Switch GoCAR-T® for HER2+ Solid Tumors
05/29/20

Bellicum Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
05/27/20

Bellicum Announces Publication of Data for GoCAR-NK™ Cell Program
05/27/20

Bellicum to Participate in Two Upcoming Virtual Investor Conferences
05/07/20

Bellicum Reports First Quarter 2020 Financial Results and Provides Operational Update
04/30/20

Bellicum Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04/15/20

Bellicum Completes Sale of Houston Facility
03/12/20

Bellicum Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Operational Update
03/05/20

Bellicum to Report Fourth Quarter and Full Year 2019 Financial Results and Provide Corporate Update
02/28/20

Bellicum Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
02/05/20

Bellicum Announces Reverse Stock Split
01/31/20

Bellicum Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
01/24/20

Bellicum Presents New Translational Data for BPX-601 at ASCO GI Cancers Symposium
01/21/20

Bellicum Pharmaceuticals Enters into Asset Purchase and Master Services Agreements with MD Anderson
01/16/20

Bellicum Pharmaceuticals to Present New Translational Data for BPX-601 at ASCO 2020 Gastrointestinal Cancers Symposium

Next: Events and Presentations

Platforms

Platforms
GoCAR Technology

Pipeline

Pipeline
GoCAR-T®
RIVO-CEL™

Publications

Scientific Publications

About Us

Leadership Team
Board of Directors
Advisory Board
Careers
Contact Us

Investors & Media

Investor Center
News & Events
Stock Information
Financial Information
Corporate Governance
Investor FAQ
Contact Us

Copyright ©2021 Bellicum Phamaceuticals, Inc. All rights reserved.

Contact Us
Privacy Policy
Terms of Use